High molecular weight kininogen (HK) is a multifunctional plasma glycoprotein that occupies a critical position in pathways that link inflammation and coagulation. It is an inhibitor of sulfhydryl proteases and has procoagulant properties. It is also a source of the vasoactive peptide bradykinin (BK). It has been previously shown that HK binds t o human umbilical vein endothelial cells (HUVEC) in culture. We have further characterized that interaction herein. Immunohistochemical experiments have indicated that when freshly obtained umbilical vein segments were treated with HK, washed, and probed with anti-HK antibodies, HK was localized on the endothelium. We next determined whether HUVEC-bound HK can be cleaved by plasma kallikrein t o release BK. Cultured HUVEC were incubated with unlabeled HK for varying times, washed, and the kinetics of BK release by plasma kallikrein were assayed by radioimmunoassay.
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RADYKININ (BK) is a vasoactive nonapeptide (Arg-
B Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg) released from high molecular weight kininogen (HK) by the action of plasma kallikrein and is known to promote venular dilation, vascular permeability, bronchoconstriction, pain, hypotension, and
The mechanisms by which BK may elicit these diverse effects have only recently begun to be addressed. For example, in vascular endothelial cells, BK has been shown to increase the uptake of L-arginine4 and induce formation of endothelium-derived relaxing factor (EDRF), which is thought to be nitric oxide?-' BK is also reported to induce activation of the phosphoinositide second messenger system and prostacylin production in vascular endothelial cells.8*y In fibroblast cultures, BK was shown to promote mitogenesis and modulate phospholipase C activity via a G-protein-dependent pathway and trigger the hydrolysis of membrane phosphatidylinositolbisphosphates to activate protein kinase C and raise intracellular calcium levels.10-12 Des-Argy BK, a cleavage product of BK and a B1 receptor agonist, has recently been shown to cause similar effects in cultured mesangial cells whose abnormal proliferation in vivo eventually leads to renal dysf~nction.~~
The morphologic changes induced in the endothelium by BK and other activating signals, such as acetylcholine, serotonin, thrombin, and calcium ionophore A23187, have been shown to render the subendothelial matrix accessible to blood components, leading to infiltration of vascular tissue by proinflammatory ~e1ls.l~ Because HK and low molecular weight kininogen (LK) are the only sources of BK in plasma and because HK has been shown to bind to cultured vascular endothelial cells specifically and saturably,15J6 generation of BK from cell-bound kininogens may be of physiologic significance. We provide evidence that HK can interact with umbilical vein endothelium in situ and that HK bound to endothelial cells in culture can be cleaved by plasma kallikrein to liberate BK.
MATERIALS AND METHODS

Materials.
Benzamidine hydrochloride monohydrate was purchased from Aldrich Chemical Company (Milwaukee, WI). Sodium citrate, polybrene, ethylenediaminetetraacetic acid (EDTA), phenylmethylsulfonyl fluoride (PMSF), soybean trypsin inhibitor, diisopropylfluorophosphate (DFP), sodium chloride, thimerosal, dithiothreitol (DTT), glucose, N-2-hydroxyethylpiperazine-N'2-ethane sulfonic acid (HEPES), radioimmunoassay (RIA) grade bovine serum albumin (BSA), calcium chloride, and dextran sulfate (average molecular weight [Mr] , 500,000) were purchased from Sigma Chemical Corp (St Louis, MO). Sodium hydroxide, sodium azide, acetic acid, phosphoric acid, and potassium chloride were purchased from Fisher Scientific Co (Fair Lawn, NJ). Sodium phosphate monobasic, Tris-base, penicillin G, streptomycin sulfate, trypsin from porcine pancreas, urea, and iodoacetamide were purchased from ICN Biochemicals (Cleveland, OH). Coomassie brilliant blue G-250 was purchased from Eastman Kodak Co (Rochester, NY). Sepharose 6 B, Mono Q FPLC columns, and ultrafiltration (Omega series) membranes were purchased from Pharmacia LKB Biotechnology Inc (Piscataway, NJ). Medium 199, amphotericin B, and 24-well culture plates were purchased from GIBCO (Grand Island, NY). Collagenase CLS-type 2 was purchased from Worthington Biochemical Corp (Freehold, NJ). Defined fetal bovine serum (FBS) was purchased from HyClone (Logan, UT). Nu-Serum was purchased from Collaborative Research Inc (Bedford, MA). Gelatin was purchased from Difco Laboratories (Detroit, MN). Zinc chloride was purchased from J.T. Baker Chemical Co (Philipsburg, NJ). Normal human plasma (NHP) and kininogen-deficient plasma were purchased from George King Bio-Medical Inc (Overland Park, KS). Plastic tissue IN) . Goat antihuman HK (light chain specific) antiserum was purchased from ICN. Normal goat serum was purchased from Sigma. Avidin-biotin complex (ABC reagent) was purchased from Pierce.
Endothelial cells were isolated from the veins of the human umbilical cords (HUVEC) and cultured according to the method of Jaffe" in gelatin-coated 60" plastic petri dishes in the presence of medium M 199 with L-glutamine, 20% FBS (heat-inactivated), 20% Nu-Serum, 100 kg/mL penicillin, 100 pg/mL streptomycin, and 2.5 p g / d amphotericin B. The cells were then passaged into gelatin-coated 75-cmz tissue culture flasks. When confluent, the cells were subcultured on gelatincoated 24-or 48-well plastic tissue culture plates in 0.5 or 0.25 mL culture medium. After reaching confluency, they were washed twice and maintained for 16 hours in M 199 with 10% Nu-Serum. The cells were identified as endothelial cells by their distinct cobblestone-like morphology and by immunofluorescent identification of factor VIII.17
Protein concentration was determined according to the method of BradfordIx or Lowry et all9 using v m a n IgG as the reference protein.
Sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE) was performed according to Laemmli.20 Gels were fixed, dried, and autoradiographed on Kodak Xomat film by exposure in the presence of an intensifying screen at -70°C.
HK was prepared from fresh NHP according to the method of Keribriou and Griffin.21 The coagulant activity of HK, determined according to Proctor and Rapaport,zz was 12.5 Uimg, where 1 U is defined as the coagulant activity present in 1 mL of pooled NHP. The purity of HK was determined by SDS-PAGE of 10 kg of purified material followed by Coomassie Blue R-250 staining. Plasma kallikrein was purified and assayed as described previouslyz3 and had a specific activity of 3.38 U/pg, where 1 U is defined as the amount of enzyme causing a change of 1.0 absorbance unit/min at 405 nm with S-2302 as substrate.
HK was iodinated with 0.5 mCi 1251-NaI by immobilized Chloramine T (Iodobeads) in 0.01 sodium acetate, 0.15 mol/L NaCl, pH 5.5, according to the manufacturer's recommendations. After iodination, unreacted lZSI-NaI was separated by desalting. The specific radioactivity, determined by trichloracetic acid (TCA) precipitation after the addition of BSA as carrier protein, ranged from 1.7 x los to 2.6 x lo9 cpmimg protein.
Labeled HK retained its clotting activity of 12 U/mL.
All binding studies were performed at the third cell passage. The HUVEC were prewashed four times over a 30-minute interval with a buffer containing 137 mmol/L NaCI, 4 mmol/L KCI, 11 mmol/L glucose, 10 mmol/L HEPES, 1 mmol/L CaClZ, and 0.5 mg/mL BSA, which was previously treated with 0.1 mmol/L PMSF to inactivate any proteolytic activity. The cells were then exposed to the above buffer containing 50 pmol/L ZnClz (binding buffer) for 20 minutes. HUVEC were then incubated with 500 pL (24-well plate) or 250 pL (48-well plate) of binding buffer containing 8.7 nmol/L HK as described in the figure legends. After incubation, the unbound material was aspirated and the cells washed four tunes with a total of 4 mL (24-well culture plates) or 2.0 mL (48-well culture plates) of binding buffer and the Endothelial cell culture.
Protein assays.
Gel electrophoresis and autoradiography.
Proteins.
Radiolabeling of HK.
Binding of HK to HUVEC. bound radioactivity was determined by solubilizing the cells in 1% SDS and counting the lysates in a gamma counter. The number of cells per well was calculated after each experiment, averaging 120,000 cells per well in a 24-well plate and 60,000 cells per well in a 48-well plate. The cell viability was greater than 95% as tested by trypan blue exclusion before and after the binding. Each measurement was in quadruplicate and the experiments were repeated twice.
Confluent HUVEC were incubated with 1 pg/mL HK and washed as described above and then incubated with the binding buffer alone or human plasma kallikrein (0.1 pg/mL) in binding buffer. Supernatants were collected at various time points and BK was determined by radioimmunoassay with lzI-Tyfi-BK as tracer.zkz6 The anti-BK antiserum used in our assays does not recognize metabolites of BK and the sensitivity of the assay is 30 to 40 pg/mL of BK.
HUVEC were incubated with 1 pg/mL lZ5I-HK in binding buffer for 60 minutes, washed, and incubated with 100 ng/mL plasma kallikrein in binding buffer for 15 seconds, 15 minutes, 30 minutes, and 60 minutes. Replicate wells were used to determine the bound cpm (to be used for calculating the amount of HK necessaly for fluid-phase digestion) as described in the previous experiment. At the end of the incubation period, the supernatant was removed and the cells were lysed with SDS-PAGE sample buffer (reducing conditions), heated at 100°C for 5 minutes, and subjected to electrophoresis on 10% gels (16 x 16 cm) on BioRad Protean I1 gel apparatus. Control experiments included incubation of HUVECbound 1251-HK with binding buffer alone. For digestion of HK in the fluid phase, free 1251-HK in binding buffer (cpm equivalent to 60-minute HUVEC-bound cpm) was incubated with 100 nglmL of kallikrein for the same time points and subjected to SDS-PAGE. The gels were subsequently dried and then subjected to autoradiography.
Immunohistochemical experiments. Freshly obtained umbilical cords were cut into 2-cm segments, washed with the binding buffer (137 mmol/L NaCI, 4 mmol/L KCI, 11 mmol/L glucose, 10 mmol/L HEPES, 1 mmol/L CaC12, 50 pmol/L ZnC12, and 0.5 mg/mL BSA) to remove any visible traces of blood in the vein, and BK generation on endothelial cells.
Kinetics of digestion of HK bound to HUVEC. For personal use only. on October 3, 2017. by guest www.bloodjournal.org From incubated with or without HK in binding buffer for 1 hour at 4°C. After incubation, the cord segments were washed with the same buffer (four times over 15 minutes), fixed in 4% paraformaldehyde for 30 minutes at room temperature, washed in phosphate-buffered saline (PBS), embedded in Tissue-Tek OCT compound, and quick-frozen in liquid nitrogen. Cryosections (4-to 6-km thick) were cut and mounted on glass slides previously treated with polylysine and stored frozen until processed. Sections were first immersed in acetone, rehydrated with PBS, and were treated with goat antihuman HK (light chain specific) antiserum or normal goat serum at 1:200 dilution for 2 hours at 37°C. After the primary antibody treatment, the sections were washed and treated with biotin-labeled rabbit antigoat antibodies (Jackson Immunoresearch, West Grove, PA) for 2 hours at 37°C before being washed for 30 minutes. The slides were then treated with peroxidaselabeled avidin biotin complex at 1:200 dilution for 1 hour at 37T, washed and treated with diaminobenzidine, and mounted using ImmuMount. Rabbit anti-factor VI11 (primary) antibodies for positive controls were used at a dilution of 1:200, followed by biotin-labeled goat antirabbit antibodies and the ABC reagent as described above.
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RESULTS
Confluent HUVEC
were incubated with 1 pg/mL (8.7 pmol/mL) of purified radiolabeled HK and the time course of binding was followed. As shown in Fig 1, approximately 4 .0 pmol of HK was bound per l(r, HUVEC in 2 hours at 37°C. In the presence of a 50-fold molar excess of unlabeled HK, only 0.6 pmol of radiolabeled HK was bound at 60 minutes, indicating that the binding of HK to HUVEC is specific.lS.l6
We next determined whether endothelial cell-bound HK can function as a substrate for plasma kallikrein. HUVEC were incubated Fig3A) indicate that 85% and 89% of the total bound IZI-HK, respectively, was still associated with HUVEC at the end of 60 minutes of incubation with plasma kallikrein or buffer alone. Excess cold HK was able to displace bound I%HK (Fig 3B) , suggesting that a significant portion of cell associated HK was present on thc cell surface, reversibly bound to it. Because there was no release of BK upon kallikrein treatment of HUVEC previously not exposed to HK (Fig 2) , the data shown in Fig 3 indicate that 80% to 85% of BK released from kallikreintreated HUVEC in Fig 2 was For personal use only. on October 3, 2017. by guest www.bloodjournal.org From . _
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and 60 minutes, there was no cleavage and the banding pattern appeared similar to that found with control HK (HK Std), suggesting that therc was negligible digestion of HK. When kallikrein was added, digestion products of HK were apparent within 15 minutes at 65, 62, and 49 Kd, represcnting the heavy chain, the light chain 1, and light chain 2 of HK, respectively. The ratc of cleavage increased gradually, and by 60 minutes of digestion about 80% of HK was cleaved (densitometric scanning). On thc other hand, in fluid phase, HK was digested much more rapidly, and by 30 minutes greater than 80% of HK was converted to products; by 60 minutes, almost all of the initial radioactivity was found in the digestion products. Interestingly, the amount of light chain 2 formed in the fluid phase was relatively smaller than from cell-bound HK. These data provide evidence that HK bound to HUVEC is digested by plasma kallikrein at a slightly slower rate than HK in fluid phase. Although it has been previously shown that HK binds to HUVEC in culture, it was not known if the interaction occurs in vivo or in a setting closer to in vivo. Therefore, we tested the possibility
HK binds to HLNEC in situ.
For personal use only. on October 3, 2017. by guest www.bloodjournal.org From For personal use only. on October 3, 2017. by guest www.bloodjournal.org From of interaction in a situation in situ. Four-to 6-pm thick sections of umbilical cord segments that were previously washed and treated with (1 pmg/mL; 8.7 nmol/L) HK in binding buffer were incubated with goat anti-HK antiserum or normal goat serum and stained with horseradish peroxidase, as described in Materials and Methods. As shown in Fig 5a, a strong positive signal is seen on the innermost layer of cells (lining the lumen) of the umbilical vein in anti-HK-treated sections compared with normal serumtreated sections (Fig 5b) . Because the washing and incubation steps were performed in binding buffer that contains 500 pg/mL albumin, the signal seen in Fig 5a may represent specific interaction of HK with human umbilical vein endothelium. When HK was omitted from the binding buffer, there was no significant staining of endothelium (Fig  5c) . Next, to show that these cells were endothelial in nature, we stained a similar section for factor VI11 antigen, a known endothelial marker.17 As shown in Fig 5d, the same layer of cells that bound HK also stained positive for factor VI11 under identical conditions. When a typical cryosection was stained with hematoxylene (but not subjected to immunostaining), it was found that the nuclei of the endothelium and the underlying tissues were intact (Fig  5e) . These data provide direct in situ evidence that HK binds to HUVEC.
DISCUSSION
HK, a 115-Kd plasma glycoprotein, occupies a critical position in the pathways by which inflammation, hemostasis, and vascular tone may be linked.27,28 Activation of the contact system in plasma is initiated by autoactivation of factor XI1 to XIIa and reciprocal activation of prekallikrein and factor XI1 to generate kallikrein, factor XIIa, and factor XIIf.27 This initiates the intrinsic pathway of coagulation leading to clot formation. One of the byproducts of contact activation is BK, formed by the cleavage of HK by plasma kallikrein. Kinin-free HK thus formed is a disulfidelinked two-chain molecule with a 65-Kd heavy chain and a 56-to 62-Kd light chain that is further processed slowly to a 45-to 49-Kd light chain.21,29,30 The heavy chain has been shown to inhibit cysteine-proteases such as calpains, papain, and cathepsins B, H, and L.31-33 The light chain contains the binding site for negatively charged initiators of contact activation as well as the binding site for prekallikrein and factor XI and, therefore, constitutes the procoagulant portion of HK. 34, 35 Previous studies have shown that human HK can bind specifically to cultured HUVEC.15,16,36 However, the physiologic significance of the binding is not known. We have now performed immunohistochemical experiments with segments of freshly obtained umbilical cords and provide for the first time in situ evidence that HK can interact with vascular endothelium. As shown in Fig 5, bound HK was localized on the same cell layer of the umbilical vein that was also positive for factor VI11 antigen, confirming the endothelial nature of these cells.
To date, it is not known whether the other three components of the contact system, prekallikrein, factor XI, and factor XII, directly interact with HUVEC. Prekallikrein and factor XI may indirectly bind to the endothelium via HK, because they can bind to the light chain moiety of HK and circulate in plasma as c~m p l e x e s .~~,~~ Recently, cell membrane phospholipids have been shown to activate the contact system in the presence of zinc ions and HK in vitro, suggesting a role for contact system in vascular injury.39 It is known that the contact system proteins are depleted in septicemia and disseminated intravascular c o a g~l a t i o n ,~~.~~ and bacterial endotoxin was directly shown to activate the contact system in vitro.42 Also, an activator of factor XI1 has been found to be expressed by rabbit endothelial ~ells.4~ Therefore, under conditions of injury or inflammation, it is possible for factor XI1 to be activated, resulting in the activation of the contact system and subsequent cleavage of endothelial cell-bound HK to liberate BK. Our data (Figs 2, 3 , and 4) indicate that, while endothelial-bound HK was not significantly cleaved by endothelial cell-derived proteases under normal conditions, it was cleaved by exogenous plasma kallikrein to generate BK. It has been previously shown that neither binding of l=I-HK to HUVEC,15 nor incubation of lZSI-HK with HUVEC lysates,44 resulted in its cleavage, suggesting that HUVEC may not contain any intracellular or membrane-expressed factors that can digest HK. The effect of exogenous enzymes on endothelium-bound HK has not been studied previously. From kinetics of digestion it appears that the endothelium-bound HK is cleaved at a slower rate by plasma kallikrein than fluid-phase HK (Fig  4) , suggesting that cell-bound HK may be protected from degradation to some extent. Such diminished rate of cleavage of cell-bound HK was also observed recently for platelet-bound HK. 45 BK thus generated by kallikrein may upregulate the receptors for both HK and LK on endothelial contributing a positive feedback for further BK formation. Because the plasma half-life of BK is in the range of 15 to 30 seconds,47 the binding of HK to endothelium and generation of BK by plasma kallikrein on endothelial cell surface may be of physiologic significance. This would facilitate interaction of the newly formed BK with its endothelial cell receptors before it can be degraded by plasma kininases, and, thus, constitute a mechanism for BK-induced endothelial cell activation, plasma and inflammatory cell extravasation, and hypotension. 28. Carretero OA, Scicli AG: The kallikrein-kinin system, a paracrine vasodepressor system involved in the regulation of renal function and blood pressure. Hypertension (Japan) 12: 81, 1990 29 36. Kuna P, Kaplan AP, Reddigari SR: Human high molecular weight kininogen binds to human umbilical cord endothelial cells through its heavy chain. Blood 76: 426, 1990 37. Mandle RJ, Colman RW, Kaplan AP: Identification of prekallikrein and high molecular weight kininogen as a complex in plasma. Proc Natl Acad Sci USA 73:4179,1976 38. Thompson RE, Mandle RJ, Kaplan AP: Association of factor XI and high molecular weight kininogen in human plasma. J Clin Invest 60:1376 ,1977 39. Schousboe I: The inositol-phospholipid-accelerated activation of prekallikrein by activated factor XI1 at physiological ionic strength requires zinc ions and high-M, kininogen. Eur J Biochem 193:495,1990 For personal use only. on October 3, 2017. by guest www.bloodjournal.org From
